Multiple Sclerosis (MS) Primary Progressive
11
6
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (11)
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Home Based Functional Balance Intervention for Multiple Sclerosis
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography